# US 7,612,057 B2 · Supramolecular complexes as photoactivated DNA cleavage agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,612,057 B2
- Document ID: US7612057B2
- Status: Granted
- Kind: B2
- Application number: 11/184,840
- Filed: 2005-07-20
- Published: 2005-12-08
- Granted: 2009-11-03
- Earliest claimed: 2002-02-01
- Assignees: Virginia Tech Intellectual Properties, Inc.
- Inventors: Karen Brewer; Shawn Swavey
- Web page: https://patentgrep.com/patent/US7612057B2

## CPC

- C07F 15/0026: {without a metal-carbon linkage}
- C07F 15/0053: {without a metal-carbon linkage}
- C07F 15/008: {without a metal-carbon linkage}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The invention provides supramolecular metal complexes as DNA cleaving agents. In the complexes, charge is transferred from one light absorbing metal (e.g. Ru or Os) to an electron accepting metal (e.g. Rh) via a bridging π-acceptor ligand. A bioactive metal-to-metal charge transfer state capable of cleaving DNA is thus generated. The complexes function when irradiated with low energy visible light with or without molecular oxygen.

## Claims

### Claim 1

A method for cleaving DNA comprising the steps of combining said DNA with a supramolecular complex selected from the group consisting of:
[(2,2′-bipyridine)2Ru(2-pyridyl)pyrazine)RhCl2(2-pyridyl)pyrazine)Ru(2,2′-bipyridine)2](PF6)5;
[(2,2′-bipyridine)2Os(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis(2-pyridyl)pyrazine)Os(2,2′-bipyridine)2](PF6)5;
[(2,2′:6′,2″-terpyridine)RuCl(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis(2-pyridyl)pyrazine)RuCl(2,2′:6′,2″-terpyridine)](PF6)3; and
[(2,2′:6′,2″-terpyridine)RuCl(2,2′-bipyridimidine)RhCl2(2,2′-bipyridimidine)RuCl(2,2′:6′,2″-terpyridine)](PF6)3.
wherein said supramolecular complex is present in sufficient quantity to bind to and cleave said DNA; and
exposing said DNA to light or radiant energy sufficient to activate said supramolecular complex to cleave said DNA.

### Claim 2 (depends on 1)

The method of claim 1 wherein said light is visible light.

### Claim 3

A method for cleaving DNA comprising the steps of:
delivering to said DNA a supramolecular complex selected from the group consisting of:
[(2,2′-bipyridine)2Ru(2-pyridyl)pyrazine)RhCl2(2-pyridyl)pyrazine)Ru(2,2′-bipyridine)2](PF6)5;
[(2,2′-bipyridine)2Os(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis(2-pyridyl)pyrazine)Os(2,2′-bipyridine)2](PF6)5;
[(2,2′:6′,2″-terpyridine)RuCl(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis(2-pyridyl)pyrazine)RuCl(2,2′:6′,2″-terpyridine)](PF6)3;
[(2,2′:6′,2″-terpyridine)RuCl(2,2′-bipyridimidine)RhCl2(2,2′-bipyridimidine)RuCl(2,2′:6′,2″-terpyridine)](PF6)3; and
pharmaceutically acceptable salts thereof, and
applying light or radiant energy to said DNA and said supramolecular complex,
wherein said step of applying light induces the production of a metal-to-metal charge transfer state within said supramolecular complex, and wherein said metal-to-metal charge transfer state mediates the cleavage of said DNA.

### Claim 4 (depends on 3)

The method of claim 3, wherein said light is visible light.

### Claim 5 (depends on 3)

The method of claim 3, wherein said DNA is in a hyperproliferating cell.

### Claim 6 (depends on 5)

The method of claim 5, wherein said hyperproliferating cell is a member selected from the group consisting of leukemia cells, ovarian cancer cells, Burkitt's lymphoma cancer cells, breast cancer cells, gastric cancer cells, and testicular cancer cells.

### Claim 7 (depends on 3)

The method of claim 3, wherein said DNA is in a non-malignant hyperproliferating cell.

### Claim 8 (depends on 7)

The method of claim 7, wherein said non-malignant hyperproliferating cell is in an organism having psoriasis, warts or macular degeneration.